The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Navari, Rudolph
One or more keywords matched the following items that are connected to Navari, Rudolph
Item TypeName
Concept Quinuclidines
Academic Article Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Academic Article Emerging drugs for chemotherapy-induced emesis.
Academic Article Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Academic Article Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
Academic Article Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
Academic Article Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Academic Article Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
Academic Article A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Academic Article The current status of the use of palonosetron.
Academic Article The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Academic Article Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
Academic Article Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Academic Article 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Academic Article Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Academic Article Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Academic Article Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Academic Article Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Search Criteria
  • Quinuclidines